Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations

Feb 09 2017

• By Joseph Haas

Malignant effusion: Pleural fluid cytology of lung (pulmonary) adenocarcinoma, a type of non small cell carcinoma.

Related Content

Merck's <em>Keytruda</em> Reaches Blockbuster Status, But Still Lags In Lung Cancer

Feb 03 2017

Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing

Feb 03 2017

Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain

Jan 21 2017

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Oct 19 2016

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

Under Fire, Bristol Plans To Pick Up The IO Pieces

Jan 27 2017

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

AstraZeneca PLC

Additional Topics

ImmunoOncology Market Intelligence Launches Commercial Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window